课题基金 / 基金详情

Development of Fiber-Mutant Adenovirus Vectors for targeting gene therapy

Development of Fiber-Mutant Adenovirus Vectors for targeting gene therapy
用于靶向基因治疗的纤维突变腺病毒载体的开发
批准号:
13672282
负责人:
NAKAGAWA Shinsaku
金额:
$2.3万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2001
资助国家:
日本
项目状态:
已结题
起止时间:
2001 至 2002

项目摘要

项目成果

NAKAGAWA Shinsaku的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
We have demonstrated the usefulness of dendritic cells (DCs) genetically modified by adenovirus vectors (Ad) to immunotherapy, while sufficient gene transduction into DCs is required for high doses of Ad. The RT-PCR analysis revealed that the relative resistance of DCs to Ad-mediated gene transfer is due to the absence of Coxsackie-adenovirus receptor expression, and that DCs expressed adequate alpha(v)-integrins. Therefore, we investigated whether fiber-mutant Ad containing the Arg-Gly-Asp (RGD) sequence in the fiber knob can efficiently transduce and express high levels of the LacZ gene into DCs. The gene delivery by fiber-mutant Ad was more efficient than that by conventional Ad in both murine DC lines and normal human DCs (NHDC). Furthermore, NHDC transduced with fiber-mutant Ad and conventional Ad at 8000-vector particles/cell resulted in a 70-fold difference in beta-galactosidase activity. We propose that alpha(v)-integrin-targeted Ad is a very powerful tool with which to implement DC-based vaccination strategies.
期刊论文(15)
专著(0)
科研奖励(0)
会议论文
N.OKADA: "Efficient Antigen Gene Transduction Using Arg-Gly-Asp Fiber-Mutant Adenovirus Vectors Can Potentiate Antitumor Vaccine Efficacy and Maturation of Murine Dendritic Cells"Cancer Res.. 61・21. 7913-7919 (2001)
N.OKADA:“使用精氨酸-甘氨酸-天冬氨酸纤维突变腺病毒载体进行有效的抗原基因转导可以增强抗肿瘤疫苗的功效和鼠树突状细胞的成熟”Cancer Res.. 7913-7919 (2001)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
S. Nakagawa et al.: "Tetracycline-regulatable adenovirus vectors: pharmacologic properties and clinical potential"Eur. J. Pharm. Sci.. 13. 53-60 (2001)
S. Nakakawa 等人:“四环素可调节腺病毒载体:药理学特性和临床潜力”Eur。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Y.Okada: "Tumor Necrosis Factor alfa-Gene Therapy for an Established Miurine Melanoma Using RGD (Arg-Gly-Asp) Fiber-mutant Adenovirus Vectors"Jpn. J. Cncer Res.. 93. 436-444 (2002)
Y.Okada:“使用 RGD (Arg-Gly-Asp) 纤维突变腺病毒载体对已确定的 Miurine 黑色素瘤进行肿瘤坏死因子 α 基因治疗”Jpn。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Y.Okada: "Tumor Necrosis Factor alfa-Gene Therapy for an Established Murine Melanoma Using RGD (Arg-Gly-Asp) Fiber-mutant Adenovirus Vectors"Jpn. J. Cncer Res.. 93. 436-444 (2002)
Y.Okada:“使用RGD(精氨酸-甘氨酸-天冬氨酸)纤维突变腺病毒载体对已建立的小鼠黑色素瘤进行肿瘤坏死因子α基因治疗”Jpn。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
13
    Exploration of adjuvant for optimization of transcutaneous vaccine
    • 批准号:
      25670076
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.41万
    • 财政年份:
      2013
    • 负责人:
      NAKAGAWA Shinsaku
    • 依托单位:
    Development of a novel transcutaneous vaccination device using a dissolving microneedle array.
    • 批准号:
      23659079
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.5万
    • 财政年份:
      2011
    • 负责人:
      NAKAGAWA Shinsaku
    • 依托单位:
    Development of a tumor diagnosis system using novel immuno-PET/MRI probe
    • 批准号:
      22300337
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $10.65万
    • 财政年份:
      2010
    • 负责人:
      NAKAGAWA Shinsaku
    • 依托单位:
    Development of nanomedicine system based the control of intracellular pharmacokinetics.
    • 批准号:
      15310093
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $8.38万
    • 财政年份:
      2003
    • 负责人:
      NAKAGAWA Shinsaku
    • 依托单位:
    海外基金